Drug Trial Radar · NCT07235293
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jan 16, 2026
Primary completion
Sep 30, 2026
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Kahr Bio Australia Pty LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Novotech (Australia) Pty Limited
- First posted
- Nov 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.
Conditions
- Colorectal Cancer
Interventions
DSP107 + AtezolizumabDrug
DSP107 infusion begins \~30 (±10) minutes after completion of atezolizumab infusion on Day 1.
FruquintinibDrug
5 mg orally, once daily (with or without food), on Days 1-21 of each 28-day cycle, followed by 7 days off.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine Median overall survival (mOS) in participants treated with the combination of DSP107 and atezolizumab versus fruquintinib.Time frame: From Day 1 until date of death from any cause assessed up to 2 years
Locations
18 sites in 2 countries. Site status is shown where the registry gives one.
University of Colorado Hospital- Anschutz Cancer Center Pavillion (ACP)
Aurora, Colorado · Recruiting
University of Colorado Cancer Center - Highlands Ranch Hospital
Highlands Ranch, Colorado · Recruiting
Mayo Clinic
Florida City, Florida · Recruiting
Duke University Medical Center - Duke Cancer Center
Durham, North Carolina · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
The University of Texas MD Anderson Cancer Center
Texas City, Texas · Recruiting
The Queen Elizabeth Hospital
Woodville, Adelaide, Australia · Recruiting
Chris O'brien Lifehouse
Camperdown, New South Wales, Australia · Recruiting
Port Macquarie Base Hospital (Mid North Coast Cancer Institute), Wrights Road,
Port Macquarie, New South Wales, Australia · Recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
Icon Cancer Centre
South Brisbane, Queensland, Australia · Recruiting
Flinders Medical Centre SA
Bedford Park, South Australia, Australia · Recruiting
Monash Health
Clayton, Victoria, Australia · Recruiting
Footscray Hospital - Western Health
Footscray, Victoria, Australia · Recruiting
Austin Health
Heidelberg, Victoria, Australia · Recruiting
Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Sunshine Hospital - Western Health
Saint Albans, Victoria, Australia · Recruiting
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.